BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 38549698)

  • 1. Germline STAT3 gain-of-function mutations in primary immunodeficiency: Impact on the cellular and clinical phenotype.
    Faletti L; Ehl S; Heeg M
    Biomed J; 2021 Aug; 44(4):412-421. PubMed ID: 34366294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activating mutations of STAT3: Impact on human growth.
    Gutiérrez M
    Mol Cell Endocrinol; 2020 Dec; 518():110979. PubMed ID: 32818584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Janus kinase inhibitors ameliorate clinical symptoms in patients with STAT3 gain-of-function.
    Kaneko S; Sakura F; Tanita K; Shimbo A; Nambu R; Yoshida M; Umetsu S; Inui A; Okada C; Tsumura M; Yamada M; Suzuki H; Kosaki K; Ohara O; Shimizu M; Morio T; Okada S; Kanegane H
    Immunother Adv; 2023; 3(1):ltad027. PubMed ID: 38549698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JAK inhibitor treatment for inborn errors of JAK/STAT signaling: An ESID/EBMT-IEWP retrospective study.
    Fischer M; Olbrich P; Hadjadj J; Aumann V; Bakhtiar S; Barlogis V; von Bismarck P; Bloomfield M; Booth C; Buddingh EP; Cagdas D; Castelle M; Chan AY; Chandrakasan S; Chetty K; Cougoul P; Crickx E; Dara J; Deyà-Martínez A; Farmand S; Formankova R; Gennery AR; Gonzalez-Granado LI; Hagin D; Hanitsch LG; Hanzlikovà J; Hauck F; Ivorra-Cortés J; Kisand K; Kiykim A; Körholz J; Leahy TR; van Montfrans J; Nademi Z; Nelken B; Parikh S; Plado S; Ramakers J; Redlich A; Rieux-Laucat F; Rivière JG; Rodina Y; Júnior PR; Salou S; Schuetz C; Shcherbina A; Slatter MA; Touzot F; Unal E; Lankester AC; Burns S; Seppänen MRJ; Neth O; Albert MH; Ehl S; Neven B; Speckmann C
    J Allergy Clin Immunol; 2024 Jan; 153(1):275-286.e18. PubMed ID: 37935260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ex vivo effect of JAK inhibition on JAK-STAT1 pathway hyperactivation in patients with dominant-negative STAT3 mutations.
    Lobo PB; Guisado-Hernández P; Villaoslada I; de Felipe B; Carreras C; Rodriguez H; Carazo-Gallego B; Méndez-Echevarria A; Lucena JM; Aljaro PO; Castro MJ; Noguera-Uclés JF; Milner JD; McCann K; Zimmerman O; Freeman AF; Lionakis MS; Holland SM; Neth O; Olbrich P
    J Clin Immunol; 2022 Aug; 42(6):1193-1204. PubMed ID: 35507130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recapitulating primary immunodeficiencies with expanded potential stem cells: Proof of concept with STAT1 gain of function.
    Liu X; Chan VSF; Smith KGC; Ming C; Or CS; Tsui FTW; Gao B; Cook MC; Liu P; Lau CS; Li PH
    J Allergy Clin Immunol; 2024 Apr; 153(4):1125-1139. PubMed ID: 38072195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. STAT1 Gain-of-Function and Hidradenitis Suppurativa Successfully Managed with Baricitinib.
    Olbrich P; Cortés JI; Neth O; Blanco-Lobo P;
    J Clin Immunol; 2023 Jul; 43(5):898-901. PubMed ID: 36881346
    [No Abstract]   [Full Text] [Related]  

  • 8. STAT3 gain-of-function syndrome.
    Vogel TP; Leiding JW; Cooper MA; Forbes Satter LR
    Front Pediatr; 2022; 10():770077. PubMed ID: 36843887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monogenic early-onset lymphoproliferation and autoimmunity: Natural history of STAT3 gain-of-function syndrome.
    Leiding JW; Vogel TP; Santarlas VGJ; Mhaskar R; Smith MR; Carisey A; Vargas-Hernández A; Silva-Carmona M; Heeg M; Rensing-Ehl A; Neven B; Hadjadj J; Hambleton S; Ronan Leahy T; Meesilpavikai K; Cunningham-Rundles C; Dutmer CM; Sharapova SO; Taskinen M; Chua I; Hague R; Klemann C; Kostyuchenko L; Morio T; Thatayatikom A; Ozen A; Scherbina A; Bauer CS; Flanagan SE; Gambineri E; Giovannini-Chami L; Heimall J; Sullivan KE; Allenspach E; Romberg N; Deane SG; Prince BT; Rose MJ; Bohnsack J; Mousallem T; Jesudas R; Santos Vilela MMD; O'Sullivan M; Pachlopnik Schmid J; Průhová Š; Klocperk A; Rees M; Su H; Bahna S; Baris S; Bartnikas LM; Chang Berger A; Briggs TA; Brothers S; Bundy V; Chan AY; Chandrakasan S; Christiansen M; Cole T; Cook MC; Desai MM; Fischer U; Fulcher DA; Gallo S; Gauthier A; Gennery AR; Gonçalo Marques J; Gottrand F; Grimbacher B; Grunebaum E; Haapaniemi E; Hämäläinen S; Heiskanen K; Heiskanen-Kosma T; Hoffman HM; Gonzalez-Granado LI; Guerrerio AL; Kainulainen L; Kumar A; Lawrence MG; Levin C; Martelius T; Neth O; Olbrich P; Palma A; Patel NC; Pozos T; Preece K; Lugo Reyes SO; Russell MA; Schejter Y; Seroogy C; Sinclair J; Skevofilax E; Suan D; Suez D; Szabolcs P; Velasco H; Warnatz K; Walkovich K; Worth A; ; Seppänen MRJ; Torgerson TR; Sogkas G; Ehl S; Tangye SG; Cooper MA; Milner JD; Forbes Satter LR
    J Allergy Clin Immunol; 2023 Apr; 151(4):1081-1095. PubMed ID: 36228738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three Adult Cases of STAT1 Gain-of-Function with Chronic Mucocutaneous Candidiasis Treated with JAK Inhibitors.
    Borgström EW; Edvinsson M; Pérez LP; Norlin AC; Enoksson SL; Hansen S; Fasth A; Friman V; Kämpe O; Månsson R; Estupiñán HY; Wang Q; Ziyang T; Lakshmikanth T; Smith CIE; Brodin P; Bergman P
    J Clin Immunol; 2023 Jan; 43(1):136-150. PubMed ID: 36050429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment of oral potentially malignant lesions with ruxolitinib in STAT3 gain-of-function disease.
    Mulvihill C; Fitzgerald K; O'Regan E; Healy CM; Leahy TR
    Oral Oncol; 2022 Sep; 132():106015. PubMed ID: 35809509
    [No Abstract]   [Full Text] [Related]  

  • 12. A Novel
    Deng M; Li Y; Li Y; Mao X; Ke H; Liang W; Lei X; Lau YL; Mao H
    Front Immunol; 2022; 13():866638. PubMed ID: 35677041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of JAK Inhibitors in Pediatric Patients with STAT1 Gain of Function (GOF) Mutations-10 Children and Review of the Literature.
    Deyà-Martínez A; Rivière JG; Roxo-Junior P; Ramakers J; Bloomfield M; Guisado Hernandez P; Blanco Lobo P; Abu Jamra SR; Esteve-Sole A; Kanderova V; García-García A; Lopez-Corbeto M; Martinez Pomar N; Martín-Nalda A; Alsina L; Neth O; Olbrich P
    J Clin Immunol; 2022 Jul; 42(5):1071-1082. PubMed ID: 35486339
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.